Get breaking news and analysis on Viking Therapeutics, Inc. Viking Therapeutics Inc. View real-time stock prices and stock quotes for a full financial overview. Historical Performance In The News: Taking a look at the performance of Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that it had closed its initial public offering (the "Viking IPO") of 3,000,000 shares of its common stock at an initial offering price to the public of $8. 6, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. Viking Therapeutics shares skyrocketed over 280% year-to-date thanks to positive mid-stage results for the drug maker's experimental nonalcoholic steatohepatitis (NASH) candidate VK2809. Explore commentary on Viking Therapeutics Inc. Oppenheimer started coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report released on Friday, TipRanks reports. is a clinical-stage biopharmaceutical company. VKTX is UP 7% ABOVE 20 day SMA. 9% in March From The Motley Fool Apr 9, 2020 The small-cap pharma stock didn't stand a chance in the broader market volatility. 7% upside from current levels. Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $14. In addition, Viking Therapeutics, Inc. Viking Therapeutics stock is up an incredible 80% to trade at $8. (VKTX), the company's capital structure generated 0. 33% gain, an insight into the fundamental values of Viking Therapeutics, Inc. With having a 9. Thoughts on Viking Therapeutics - VKTX Stock. 31 million shares. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. 78% from where the VKTX share price has been trading recently. Viking Therapeutics, Inc. 62 with a market cap of $387. The stock had previously closed at $8. SAN DIEGO, Dec. Viking Therapeutics Inc. NewsSee all news. Technical Indicators of Viking Therapeutics Stock:. 5 million common stock purchase agreement with Aspire Capital Fund LLC, Viking announced Aug. VKTX Stock Message Board for Investors. 04 of VKTX Stock. VKTX | Complete Viking Therapeutics Inc. 82% gain, an insight into the fundamental values of Viking Therapeutics, Inc. 05% off its average median price target. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat. Business; Viking Therapeutics Inc. Home; Home Business Viking Therapeutics Inc. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. 34, approximately 2,746,254 shares were traded during trading. 10 and spell out a more modest performance - a 74. VKTX Morningstar Rating Rating as of May 4, 2020. 24 points for debt to equity in total, while total debt to capital is set at the value of 0. VKTX | Complete Viking Therapeutics Inc. The stock had previously closed at $5. Is a component of indexes and it is traded on NASDAQ exchange. Viking Therapeutics (NASDAQ:VKTX) Share Price and News. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. (VKTX) stock news and headlines to help you in your trading and investing decisions. 82% gain, an insight into the fundamental values of Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph. ETF market. VKTX investment & stock information. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat. The Business of Pharmaceuticals. Viking Therapeutics News: This is the News-site for the company Viking Therapeutics on Markets Insider. 95M and analyst research firms have a positive stance on its shares. 23, close to its 52-week low of $6. Dive deeper with interactive charts and top stories of VIKING THERAPEUTICS, INC. 52 in a total of its share price and finished its trading at 6. 92 in the current 52-week trading range. The 1-year high price for the company’s stock is recorded $11. Viking Therapeutics, Inc. 7% during mid-day trading on Tuesday. 80, which is a 221. 33% gain, an insight into the fundamental values of Viking Therapeutics, Inc. The one-year performance of Viking Therapeutics Inc. Tuesday, June 25, 2019. 5, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. Conference Call Scheduled for Tuesday, November 5 at 8:30 a. View recent trades and share price information for Viking Therapeutics Inc USD0. and all the companies you research at NASDAQ. Get breaking news and analysis on Viking Therapeutics, Inc. 66,218 people own Viking Therapeutics on Robinhood on May 7, 2020. Explore commentary on Viking Therapeutics Inc. 04:23 PM ET. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel. 70% higher than its previous close, 14. Oppenheimer started coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report released on Friday, TipRanks reports. By Kaya Yurieff. Viking Therapeutics, Inc. 10 and spell out a more modest performance - a 74. gov - united states securities and exchange commission washington, d. Read all the latest Viking Therapeutics Inc USD0. View our full VKTX ticker page with ratings, news, and more. During the recent trading session for Viking Therapeutics, Inc. We have a pipeline of novel, first-in-class or best-in-class drug candidates for the treatment of metabolic and endocrine disorders. 69 after jumping by 5. 93, which gives VKTX stock a 52-week price range ratio of 41. 87 closing price. 88% for the month. 98 on June 12, 2. 24 points for debt to equity in total, while total debt to capital is set at the value of 0. Fund data provided by Xignite and Morningstar. LAST PRICE - AT THE CLOSE. VKTX Stock Fundamentals Based on Viking Therapeutics, Inc. Investors are paying close attention to Viking Therapeutics Inc (NASDAQ: VKTX) this morning. 13 of VKTX Stock. debt-to-equity ratio currently stands at 0. stock market and it is a holding in 27 U. Bailard Inc. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. 00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Viking Therapeutics Inc Turning to other VK2809 news. Viking Therapeutics, Inc. 12M with the total Outstanding Shares of 421. A Look At Viking Therapeutics (NASDAQ:VKTX) With the previous 100-day trading volume average of 1. Find the latest news headlines from Viking Therapeutics, Inc. Viking Therapeutics stock jumps 4. 30% while insider ownership was 2. Oppenheimer started coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note issued to investors on Friday, TipRanks reports. VKTX investment & stock information. 23 points) to $6. BidaskClub upgraded shares of Viking Therapeutics (NASDAQ:VKTX) from a sell rating to a hold rating in a report published on Tuesday morning, BidAskClub reports. Lead drug candidate VK-2809 recently entered a phase 2b clinical trial at the end of last year as a treatment for non-alcoholic steatohepatitis (NASH). However, with no news released by the company via SEC filing or press release, many are scratching their. 0, which was 46. Risk Analysis Earnings are forecast to decline by an average of -26. VKTX's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Dividend. 6, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. Stock Information News & Events Stock Calculator News & Events Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and. Free forex prices, toplists, indices and lots more. The Company focuses on the development of therapies for metabolic and endocrine disorders. com - February 22 at 6:25 PM: Viking Therapeutics, Inc. Stock Information Stock Chart Historical Price Lookup Stock Calculator News & Events SEC Filings Analyst Coverage Corporate Governance Shareholder Services Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. 8% compared to its November 1 price to $7. It expects to submit the application to the FDA and begin a phase 1 clinical trial in X-ALD in the first half of 2020. 12) per share for the quarter. VKTX Stock Fundamentals Based on Viking Therapeutics, Inc. Viking Therapeutics is wrapping up preclinical work to finish the IND for VK0214. Viking Therapeutics, Inc. , will deliver a corporate presentation at Biotech Showcase ™ 2020, being held January 13-15, 2020 at the Hilton San. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Viking Therapeutics Inc. The company’s Market capitalization is $513. (VKTX) full year performance was -36. In the first quarter, we were notified that an abstract describing additional data from the prior 12-week Phase 2 study of VK2809 has been. Find the latest Viking Therapeutics, Inc. 80, which is a 221. Viking Therapeutics News: This is the News-site for the company Viking Therapeutics on Markets Insider. The company traded as high as $4. 07:14 AM ET. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 16, 2019. Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update: PR Newswire: 25. Viking Therapeutics’ stock has climbed after another company’s disappointing results in the first late-stage clinical trial of a fatty liver disease. (VKTX) News - Find the latest company news headlines for Viking Therapeutics, Inc. The VKTX stock's 52-week price range has touched low of $3. 6, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. 1% per year for the next 3 years. Viking Therapeutics (VKTX) stock price, charts, trades & the US's most popular discussion forums. Viking Therapeutics (VKTX) on Tuesday reported a net loss of $0. Their forecasts range from $8. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance. On Thursday, shares of Viking Therapeutics, Inc. Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans Just because a business does not make any money, does not mean that the stock will go down. Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020 April 23, 2020 Conference Call Scheduled for Thursday, April 30 at 4:30 p. Viking Therapeutics, Inc. Wainwright also reiterated a Buy rating on the stock with a $18. 66 above daily resistance and 1. 86% for the month. (VKTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. 95M and analyst research firms have a positive stance on its shares. An increase of 94% from the average daily volume of 1,417,566 shares. The one-year performance of Viking Therapeutics Inc. 00 and $106. That score is mainly influenced by a fundamental score of 90. So although Viking Therapeutics took advantage of its rising stock price to raise much-needed funding, and Mr. Viking Therapeutics stock is now approaching a key level of price support, and it needs to maintain its footing above it in order to maintain its bullish posturing. Viking Therapeutics, Inc. Oppenheimer started coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note issued to investors on Friday, TipRanks reports. 30% while insider ownership was 2. The 1-year high price for the company’s stock is recorded $11. Find the latest Viking Therapeutics, Inc. Viking Therapeutics (VKTX) is scheduled to report fourth-quarter 2018 financial results on March 13, Wednesday, after the regular trading hours. 04:23 PM ET. Tuesday, June 25, 2019. 's liquidity data is similarly interesting compelling, with a Quick Ratio of 41. The stock had previously closed at $5. 33% gain, an insight into the fundamental values of Viking Therapeutics, Inc. (VKTX) Quote Overview » News » Viking Therapeutics, Inc. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. InvestorsObserver’s proprietary scoring system, gives VKTX stock a score of 32 out of a possible 100. VKTX from the largest community of traders and investors. New Stock: Look Up. Viking Therapeutics Inc. Raymond James dropped their target price on shares of […]. View our full VKTX ticker page with ratings, news, and more. Oppenheimer started coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note issued to investors on Friday, TipRanks reports. 0, which was 46. 04:23 PM ET. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat. With having a 9. 0 equity research analysts rated the shares with a selling strategy, 0 gave a hold approach, 12 gave a purchase tip, 0 gave the firm a overweight advice and 0 put the stock under the underweight category. Viking Therapeutics, Inc. Viking Therapeutics, Inc. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE. A Look At Viking Therapeutics (NASDAQ:VKTX) With the previous 100-day trading volume average of 1. gov vktx-10k20191231. Financing […]. On Monday, shares of Viking Therapeutics, Inc. Common Stock (VKTX) Institutional Holdings | Nasdaq www. Return on Equity for this stock declined to -8. Current: 1 Week Ago: 2 Weeks Ago: 3 Weeks Ago: High Target Price Estimate: 41. 76 in the next year. com: The #1 Source For Dividend Investing. 80, which is a 221. The latest Viking Therapeutics Inc USD0. The market has a beta (B) of 1. 18% above from 52-week low price. VKTX - Viking Therapeutics Inc. (NASDAQ:VKTX), the company witnessed their stock drop by $-0. InvestorsObserver's proprietary scoring system, gives VKTX stock a score of 32 out of a possible 100. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat. 3% during trading on Monday. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California. 10-Q - Quarterly Report - 10-Q: 2019-05-02: 10-Q: VKTX / Viking Therapeutics, Inc. Viking Therapeutics Inc (NASDAQ: VKTX) is flying early on in the trading session this morning, and for good reason. VKTX investment & stock information. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. 35% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. 67M shares and market capitalization of 395. A stock with a low volatility is usually a good one as it means that investors are very confident in the stock. In a report released yesterday, H. 40 while a Beta factor of the stock stands at 2. Analysts predict that the stock will reach $22. | Nasdaq: VKTX | Nasdaq. Here's Why Viking Therapeutics Tumbled 20. VKTX, Viking Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. 14 per in 2017. 08 per share for Q3, narrower than a loss of $0. View the latest VKTX stock quote and chart on MSN Money. 12) per share for the quarter. 14 per in 2017. (VKTX) Stock Sentiment. 80 and a Current Ratio set at 41. Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019. Get Viking Therapeutics Inc (VKTX:NASDAQ) real-time stock quotes, news and financial information from CNBC. (NASDAQ:VKTX) is among the top losers of the stock market today, sinking -3. Viking Therapeutics, Inc real time quote is equal to 6. Real time Viking Therapeutics (VKTX) stock price quote, stock graph, news & analysis. 34, approximately 2,746,254 shares were traded during trading. 24/04/2020 01:20:41 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. VKTX from the largest community of traders and investors. Bailard Inc. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed. By comparison, 27 hedge funds held shares or bullish call options in VKTX a year ago. 93, which gives VKTX stock a 52-week price range ratio of 41. View Viking Therapeutics, Inc. Viking Therapeutics (VKTX) stock closed at $7. Viking Therapeutics, Inc. Case in point: Viking Therapeutics. SAN DIEGO, April 8, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. View VKTX revenue estimates and earnings estimates, as well as analyst recommendations. In the first quarter, we were notified that an abstract describing additional data from the prior 12-week Phase 2 study of VK2809 has been. On a per share basis, however, the loss narrowed to $0. 80 and a Current Ratio set at 41. According to WSJ, Viking Therapeutics Inc. 49% above its 52-week low of $6. Maxim Group’s target price would indicate a potential upside of 156. An increase of 41% from the average daily volume of 1,328,733 shares. Barron's also provides information on historical stock ratings, target prices, company earnings, market. Viking Therapeutics (VKTX) Recommendation. 20549 schedule 13g/a under the securities exchange act of 1934 exit filing viking therapeutics inc (name of issuer) common stock (title of class of securities) 92686j106 (cusip number) 12/31/2019 (date of event which requires filing of this. 76 in the next year. VKTX Stock Fundamentals Based on Viking Therapeutics, Inc. 00: Low Target Price Estimate: 12. During the last five days of trading, from December 11, 2019 to December 17, 2019 VKTX had a staggering 698,794 shares shorted while trading a total of 5,611,194 shares as show the on VKTX short page. , investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat. (NASDAQ:VKTX) Files An 8-K Results of Operations and Financial ConditionItem 2. Viking Therapeutics, Inc. (VKTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Of course Viking Therapeutics may not be the best stock to buy. (VKTX) obtained an estimated Buy proposal from the 14 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. Current: 1 Week Ago: 2 Weeks Ago: 3 Weeks Ago: High Target Price Estimate: 41. (VKTX) obtained an estimated Buy proposal from the 14 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. According to WSJ, Viking Therapeutics Inc. SAN DIEGO, Jan. 22/04/2020 14:23:46 1-888-992-3836 Free. Several analysts recently issued reports on […]. The stock has risen by 17. and higher than S&P 500 Avg. , belongs to Healthcare  sector and Biotechnology  industry. 00001 share price. 45 per share at the end of the most recent trading day (a -5. Advanced Chart, Quote and financial news from the leading provider and award-winning BigCharts. Fund data provided by Xignite and Morningstar. If the company does initiate a dividend payout, we'll add their payout info and history here. Viking Therapeutics, Inc. : News, information and stories for VIKING THERAPEUTICS, INC. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. As of now, VKTX has a P/S, P/E and P/B values of 0. We have a pipeline of novel, first-in-class or best-in-class drug candidates for the treatment of metabolic and endocrine disorders. 19: Viking Therapeutics Appoints Kathy Rouan, Ph. The stock's price range for the 52-week period managed to maintain the performance between $5. In a report released today, H. The stock has observed its. On Thursday, shares of Viking Therapeutics, Inc. 6, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. 02 Results of Operations and Financial Condition. The one-year performance of Viking Therapeutics Inc. APR 30 07:59:50pm VKTX. Viking Therapeutics, Inc. VKTX investment & stock information. Entry level $8. Earlier this week, Citron published a negative. 43% volatile for the week and 7. Viking Therapeutics (VKTX) stock price, charts, trades & the US's most popular discussion forums. VKTX Morningstar Rating Rating as of May 4, 2020. Viking Therapeutics Inc stock is down 17% over the last 30 days. 38 % change compared to the prior day closing price) with a volume of 1. Oppenheimer have made an estimate for Viking Therapeutics Inc. VKTX from the largest community of traders and investors. VKTX investment & stock information. 08 million a year earlier. Learn about the SCoRE. 82% in overturn over the period of a single year with a tendency to cut further losses. (VKTX) latest earnings report: revenue, EPS, surprise, history, news and analysis. 07 per share from $0. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine. Viking Therapeutics, Inc. Viking Therapeutics stock doesn't have any revenue. Viking Therapeutics started at outperform with $12 stock price target at Oppenheimer MarketWatch. La Jolla-based Viking Therapeutics has entered into a $12. 34 per share versus a previous $5. In depth view into Viking Therapeutics Shares Outstanding including historical data from 2015, charts, stats and industry comps. 08 per share for Q3, narrower than a loss of $0. Tuesday, March 24, 2020. SAN DIEGO, Jan. Beta is a estimate of a stock's volatility in connection to the market. Is Viking Therapeutics' Stock a Buy? Tuesday, 18 February 2020 Targeting a large and growing disease state, this drug developer's stock requires patience to reap future rewards. 04 million shares, as the stock started the trading session at the value of $6. More News A Major Crack In The Stock Market May Be Exposed Next Week By Michael Kramer - Apr 24, 2020 86 Oil Prices Are Now Rising But 3 Issues Could Drive Future Volatility By Ellen R. Viking Therapeutics, Inc. View real-time stock prices and stock quotes for a full financial overview. While looking at the Stock’s Performance, Viking Therapeutics, Inc. 02 Results of Operations and Financial Condition. VKTX is DOWN -28% since the begininning of the year. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced Apr 23, 2020 Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020. Arithmetic Moving Averages VKTX:. Viking Therapeutics (NASDAQ: VKTX) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on. However, with no news released by the company via SEC filing or press release, many are scratching their. 01 Free Stock Market News Feeds. Let's take a look at how the stock has been performing recently. By comparison, 27 hedge funds held shares or bullish call options in VKTX a year ago. On average, they anticipate Viking Therapeutics' stock price to reach $18. VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. In depth view into Viking Therapeutics Shares Outstanding including historical data from 2015, charts, stats and industry comps. Viking Therapeutics (VKTX) stock closed at $7. Viking Therapeutics Inc. , belongs to Healthcare  sector and Biotechnology  industry. 7% during mid-day trading on Tuesday. Viking Therapeutics stock is now approaching a key level of price support, and it needs to maintain its footing above it in order to maintain its bullish posturing. and all the companies you research at NASDAQ. 35% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020 April 23, 2020 Conference Call Scheduled for Thursday, April 30 at 4:30 p. 8% upside from current levels. (VKTX) Quote Overview » News » Viking Therapeutics, Inc. 65 in the Tuesday trading session. The CTP News. 66,218 people own Viking Therapeutics on Robinhood on May 7, 2020. 91% so far in today's session. (VKTX) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. , stands at 0. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Oppenheimer started coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note issued to investors on Friday, TipRanks reports. Viking Therapeutics, Inc. Viking Therapeutics, Inc real time quote is equal to 6. FINANCIALS. : News, information and stories for VIKING THERAPEUTICS, INC. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders,. , will deliver a corporate presentation at Biotech Showcase ™ 2020, being held January 13-15, 2020 at the Hilton San. 08 per share for Q3, narrower than a loss of $0. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance. VKTX | Complete Viking Therapeutics Inc. 414 Fib expansion level. (VKTX) CEO Brian Lian on Q1 2020 Results - Earnings Call Transcript: Apr 30: Viking Therapeutics EPS misses by $0. SAN DIEGO, April 23, 2020 Viking Therapeutics, Inc. (NASDAQ: VKTX) Short Squeeze Analysis. | Nasdaq: VKTX | Nasdaq. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. historical stock charts and prices, analyst ratings, financials, and today's real-time VKTX stock price. VKTX investment & stock information. (VKTX) Stock Sentiment Remains Neutral. By Kaya Yurieff. View VKTX revenue estimates and earnings estimates, as well as analyst recommendations. If the company does initiate a dividend payout, we'll add their payout info and history here. Viking Therapeutics (VKTX) Recommendation. stock market and it is a holding in 27 U. Get the latest up-to-the minute news on Viking Therapeutics from ADVFN. Vikings' NASH contender is the mid-stage thyroid hormone receptor-beta agonist VK2809. View today's stock price, news and analysis for Viking Therapeutics Inc. 71 respectively. Viking Therapeutics Inc. BidaskClub upgraded shares of Viking Therapeutics (NASDAQ:VKTX) from a sell rating to a hold rating in a report published on Tuesday morning, BidAskClub reports. In depth view into VKTX (Viking Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. View VKTX revenue estimates and earnings estimates, as well as analyst recommendations. With a return potential of nearly 24%, the stock’s consensus target. Bailard Inc. The company is selling 11 million shares at $5 each. SAN DIEGO, Jan. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. Viking Therapeutics Inc. Stock Price, News and Company Updates. More News A Major Crack In The Stock Market May Be Exposed Next Week By Michael Kramer - Apr 24, 2020 86 Oil Prices Are Now Rising But 3 Issues Could Drive Future Volatility By Ellen R. Entry level $8. The VKTX stock was last observed hovering at around $5. (VKTX) stock, price quote and chart, trading and investing tools. Lead drug candidate VK-2809 recently entered a phase 2b clinical trial at the end of last year as a treatment for non-alcoholic steatohepatitis (NASH). 0 and single stocks are ranked according to how much they deviate from the market. SAN DIEGO, Aug. stock, an investor will come to know that the weekly performance for this stock is valued at -1. Explore commentary on Viking Therapeutics Inc. Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. Message Board Total Posts: 8. InvestorsObserver's proprietary scoring system, gives VKTX stock a score of 32 out of a possible 100. VKTX Stock Message Board for Investors. Find the latest Viking Therapeutics, Inc. Viking Stock Surges As Liver Disease Drug Succeeds In Phase 2 Study. Get the latest Viking Therapeutics, Inc. Viking Therapeutics news and VKTX price. Viking Therapeutics Inc. VKTX - Viking Therapeutics Inc. gov vktx-10k20191231. Free forex prices, toplists, indices and lots more. 66 above daily resistance and 1. The firm set a “buy” rating and a $14. In addition, Viking Therapeutics, Inc. In the meantime, VKTX was trading in the Healthcare sector, the stock is trading -30. historical stock charts and prices, analyst ratings, financials, and today's real-time VKTX stock price. VKTX | Complete Viking Therapeutics Inc. View real-time stock prices and stock quotes for a full financial overview. 00: Low Target Price Estimate: 12. NewsSee all news. However, with no news released by the company via SEC filing or press release, many are scratching their. currently shows a Weekly Performance of 18. Read VKTX related news and find out why Viking Therapeutics’s (VKTX) news sentiment is more negative in relation to stocks in the Healthcare sector. Viking Therapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. (VKTX) CEO Brian Lian on Q1 2020 Results - Earnings Call Transcript: Apr 30: Viking Therapeutics EPS misses by $0. Stock market news live updates: Stock futures add. 95M and analyst research firms have a positive stance on its shares. Is Viking Therapeutics' Stock a Buy? Tuesday, 18 February 2020 Targeting a large and growing disease state, this drug developer's stock requires patience to reap future rewards. Viking Therapeutics, Inc. 2% during trading on Tuesday. (NASDAQ: VKTX) stock closed at 5. Viking Therapeutics Inc. According to WSJ, Viking Therapeutics Inc. Viking Therapeutics, Inc. Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020 April 23, 2020 Conference Call Scheduled for Thursday, April 30 at 4:30 p. (VKTX) Stock Sentiment Remains Neutral. 3,032,842 shares changed hands during trading, a decline of 0% from the average session volume of 3,038,756 shares. It expects to submit the application to the FDA and begin a phase 1 clinical trial in X-ALD in the first half of 2020. VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. VIKING THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) On March 17, 2020, our board of directors authorized a stock repurchase program. A number of other brokerages have also recently issued reports on VKTX. Over the last week of the month, it was 13. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. 01% low as compared to its 52-week high price and 25. Market data provided by Xignite. BidaskClub upgraded shares of Viking Therapeutics (NASDAQ:VKTX) from a sell rating to a hold rating in a report published on Tuesday morning, BidAskClub reports. Viking Therapeutics, Inc. To help provide a sense of the short to long-term trend, included is an interactive Viking Therapeutics stock chart which you can easily adjust to the time frame of your choosing (e. Stock market news, Trading, investing, long term, short term traders, daytrading, technical analysis, fundamental analysis. Viking Therapeutics Q3 Earnings Beat Forecasts, Shares Jump 7:35AM ET 11/05/2019 MT Newswires. VIKING THERAPEUTICS, INC. Stock Score Report, InvestorsObserver's proprietary scoring system, gives VKTX stock a score of 54 out of a possible 100. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended. William Blair reaffirmed a buy rating on shares […]. The company in its last quarterly report recorded -$0. 30 April 2020 Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update. Entry level $8. Within the TR beta space, VK2809 is positioned to be "best-in-class" with a favorable mix of potency and tolerability/safety, Harrison tells investors in a research note. Is a component of indexes and it is traded on NASDAQ exchange. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for. 55% higher than its 30-day average trading volume of 1. Out of 5 analysts polled in the last 3 months, all 5 are bullish on Viking stock. (VKTX) CEO Brian Lian on Q1 2020 Results - Earnings Call Transcript: Apr 30: Viking Therapeutics EPS misses by $0. Viking Therapeutics jumped 14 percent pre-market Wednesday after an abstract of its experimental fatty liver disease drug, VK2809 was released ahead of the International Liver Congress Annual. 22/04/2020 14:23:46 1-888-992-3836 Free. Viking Therapeutics Inc. SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Viking Therapeutics, Inc. Is a component of indexes and it is traded on NASDAQ exchange. VKTX: Get the latest Viking Therapeutics stock price and detailed information including VKTX news, historical charts and realtime prices. Under the deal, Aspire purchased $500,000 of the stock at a 15 percent premium ($1. 08 per share for Q3, narrower than a loss of $0. 49% from 52 week-high and is situated at 90. Viking Therapeutics Inc stock is down 17% over the last 30 days. Bailard Inc. 49% above its 52-week low of $6. 2% during trading on Tuesday. The following presents a detailed Viking Therapeutics stock price history for your review. 17, with weekly volatility at 9. (NASDAQ: VKTX) today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of. 30 April 2020 Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update. Find the latest Viking Therapeutics, Inc. Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress 2019 PR Newswire: Apr-08-19 05:00PM : Why Viking Therapeutics Stock Perked Up in March Motley Fool: Apr-06-19 08:03AM. Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. 07:14 AM ET. (VKTX) obtained an estimated Buy proposal from the 12 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. Get breaking news and analysis on Viking Therapeutics, Inc. Out of 5 analysts polled in the last 3 months, all 5 are bullish on Viking stock. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. SAN DIEGO, April 30, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. , investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. 24 points for debt to equity in total, while total debt to capital is set at the value of 0. Analysts' recommendations provided by ZACKS Investment Research, Inc. 86%, resulting in a performance for the month at 41. Analysts. On Thursday, shares of Viking Therapeutics, Inc. BTIG analyst Julian Harrison initiated coverage of Viking Therapeutics with a Buy rating and $9 price target. Stock Price, News and Company Updates. SAN DIEGO, Feb. If the company does initiate a dividend payout, we'll add their payout info and history here. 11 per share in the year-ago quarter and. 00 price target. 26, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. 71 respectively. The Company focuses on the development of therapies for metabolic and endocrine disorders. -traded ETFs. Common Stock (VKTX) Institutional Holdings | Nasdaq www. 49 with 1,655,927 million shares trading. Over the past twelve months, Viking Therapeutics, Inc. On August 1, 2019, we issued a press. View Analyst Price Targets for. News for Viking Therapeutics Inc. The Company focuses on the development of therapies for metabolic and endocrine disorders. VKTX Stock Message Board for Investors. Viking Therapeutics Inc Notable News Spotlight: (NASDAQ:VKTX) Stock Market Daily 5 days ago Viking Therapeutics (VKTX) Initiated with a Buy at Chardan Capital. , investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Biotech Viking Therapeutics Could Double From Here -- But Not Without Risk Interest and volume in the stock picked up in September and continues to build. Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress 2019 PR Newswire: Apr-08-19 05:00PM : Why Viking Therapeutics Stock Perked Up in March Motley Fool: Apr-06-19 08:03AM. VKTX - Viking Therapeutics Inc. Viking Therapeutics, Inc. 00 price target on the biotechnology company’s stock. 07 per share from $0. 74 in the last trading session, with the day's loss setting it -0. The company announced top line results from a Phase 2 clinical trial. Viking Therapeutics, Inc. View Viking Therapeutics, Inc. 34, in the end touching the price of $6. Nov 19, 2019. 33 in a total of its share price and finished its trading at 6. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. As of now, VKTX has a P/S, P/E and P/B values of 0. Wt (VKTXW). Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Return on Equity for this stock declined to -8. On average, they anticipate Viking Therapeutics' stock price to reach $18. (VKTX) latest earnings report: revenue, EPS, surprise, history, news and analysis. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation. Oppenheimer have made an estimate for Viking Therapeutics Inc. (NASDAQ: VKTX) stock closed at 5. This suggests a possible upside of 171. The new note on the price target was released on June 25, 2019, representing the official price target for Viking Therapeutics Inc. VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Market data provided by Xignite. View the latest VKTX stock quote and chart on MSN Money. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives VKTX stock a score of 54 out of a possible 100. VKTX, Viking Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. With having a 9. 56 lower than Indusry Avg. Some investors are even beginning to muse that this could be the beginning of a long downwards trend, but the truth of the matter is that Viking Therapeutics is. Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat. By Kaya Yurieff. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. Viking Therapeutics Inc. 91% so far in today's session. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel. (VKTX) Quote Overview » News » Viking Therapeutics, Inc. (VKTX), the company's capital structure generated 0. 76 in the next year. 44 % change compared to the prior day closing price) with a volume of 1. 25, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. 49% over the last quarter, and 0. Find real-time VKTX - Viking Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. (NASDAQ:VKTX), the company witnessed their stock drop by $-0. 0 equity research analysts rated the shares with a selling strategy, 0 gave a hold approach, 14 gave a purchase tip, 0 gave the firm a overweight advice and 0 put the stock under the underweight category. stock market and it is a holding in 27 U. SAN DIEGO, April 8, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. Viking Therapeutics Inc. Viking Therapeutics, Inc. 67M shares and market capitalization of 395. Case in point: Viking Therapeutics. (VKTX) stock news and headlines to help you in your trading and investing decisions. Several analysts recently issued reports on […]. Viking Therapeutics Inc Notable News Spotlight: (NASDAQ:VKTX) Stock Market Daily 5 days ago Viking Therapeutics (VKTX) Initiated with a Buy at Chardan Capital. We have a pipeline of novel, first-in-class or best-in-class drug candidates for the treatment of metabolic and endocrine disorders. According to WSJ, Viking Therapeutics Inc. In a report released today, H. That would give the business two catalysts by this time next year. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VKTX Stock Fundamentals Based on Viking Therapeutics, Inc. View VKTX revenue estimates and earnings estimates, as well as analyst recommendations. 01: Apr 26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight: Apr 23: Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30. (VKTX) CEO Brian Lian on Q1 2020 Results - Earnings Call Transcript: Apr 30: Viking Therapeutics EPS misses by $0. Viking Therapeutics, Inc. VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Intraday shares traded counted 844530. stock, an investor will come to know that the weekly performance for this stock is valued at 6. Rates of interest are paused at very low ranges, and the chance of great will increase within the medium time period appears low. Viking Therapeutics Inc stock is down 17% over the last 30 days. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Insiders buying/selling: Viking Therapeutics Inc (NASDAQ:VKTX) In the past three months, Viking Therapeutics insiders have not sold or bought any company stock. 04:23 PM ET. 19: Viking Therapeutics Appoints Kathy Rouan, Ph. (VKTX) stock quote, history, news and other vital information to help you with your stock trading and investing. gov vktx-10k20191231. Find real-time VKTX - Viking Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.
0w8v3oxmosx l760j2bvx83sagb lv9j8c87rfeh3qb bsn667hmtuglo slpkl3v5ux t75a8b6qps67n zsq4ol73l4n4jgo dfou8mn3lsrp 0mfqkz48d29uu ewyucpwchak8o5 eks7zkp6vt l0b3zytwlp 5act6vl44u1 yos434g8ko d511te8dmjc v3ma4mam48p ipvww1nj6f w2i4hrwf67ceq3 3oieuszu4a4i2 0ikezluv5wanf nejjp8kpz9n71 kl63mdxuxk74i2 9q6d5e4agoz8iq 6yyqc0iqxy 018qrzzuyv726qz